We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    EXHALE-4
Previous Study | Return to List | Next Study

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05748600
Recruitment Status : Recruiting
First Posted : February 28, 2023
Last Update Posted : March 3, 2023
Information provided by (Responsible Party):
Areteia Therapeutics

Brief Summary:
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.

Condition or disease Intervention/treatment Phase
Eosinophilic Asthma Asthma; Eosinophilic Asthma Attack Drug: Dexpramipexole Dihydrochloride Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 750 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
Actual Study Start Date : January 30, 2023
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : July 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: 150 mg BID
Dexpramipexole 150 mg oral tablet taken twice a day
Drug: Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet

Experimental: 75 mg BID
Dexpramipexole 75 mg oral tablet taken twice a day
Drug: Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet

Placebo Comparator: Placebo
Placebo oral tablet taken twice a day
Drug: Placebo
administration of placebo tablet

Primary Outcome Measures :
  1. Change in pre-BD FEV₁ from baseline [ Time Frame: Day 1 (baseline, pre-dose), Weeks 20, 24 ]
    Pre-bronchodilator forced expiratory volume (pre-BD) FEV₁, absolute change from baseline, averaged over Weeks 20 and 24.

Secondary Outcome Measures :
  1. Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) [ Time Frame: Day 1 (baseline, pre-dose), Weeks 20, 24 ]
    Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) averaged over visits at Weeks 20 and 24.

  2. Change from baseline in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12) [ Time Frame: Day 1 (baseline, pre-dose) through Week 24 ]
    Standardized version of the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12) change from baseline to Week 24.

  3. Change from baseline absolute eosinophil count (AEC) to Week 24. [ Time Frame: Day 1 (baseline, pre-dose) through Week 24 ]
  4. Change from baseline forced vital capacity (FVC) averaged over Weeks 20 and 24. [ Time Frame: Day 1 (baseline, pre-dose), Weeks 20, 24 ]
  5. Change from baseline forced vital capacity (FVC) at Weeks 4, 8, 12, 16, 20, and 24. [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, and 24 ]
  6. Change from baseline post-bronchodilator (post-BD) forced expiratory volume (FEV₁) at Week 24. [ Time Frame: Day 1 (baseline, pre-dose) through Week 24 ]
  7. The EuroQol 5-dimensional questionnaire (EQ-5D-5L) change from baseline to Week 24 [ Time Frame: Day 1 (baseline, pre-dose) through Week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent form and assent form, as appropriate.
  2. Male or female ≥12 years of age at randomization.

    Asthma-related criteria

  3. Documented physician diagnosis of asthma for ≥12 months.
  4. Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting β2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1.
  5. Pre-BD FEV1 ≥40% and <80% of predicted at Screening.
  6. Bronchodilator reversibility, as evidenced by ≥12% and ≥200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17).Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening Period, at an unscheduled visit at least 7 days prior to baseline.
  7. ACQ-6 ≥1.5 at Screening.
  8. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2).

    General medical history

  9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at Screening and Baseline.
  10. WOCBP must use either of the following methods of birth control, from Screening through the End of Study Visit:

    1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive.


    2. Two protocol acceptable methods of contraception in tandem.

      • Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following age specific requirements apply:
    3. Women <50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
    4. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. least 7 days prior to baseline.

Exclusion Criteria:

Asthma-related criteria

  1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization priorr to the Screening Visit up to and including the Baseline Visit.

    Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status.

  2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, or hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis).
  3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening.

    Prohibited medications/procedures

  4. Treatment with a biologic investigational drug in the last 5 months. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives, whichever is longer. Treatment with GSK3511294 (longacting anti-interleukin-5) in the past 12 months.
  5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
  6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline.
  7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days.
  8. Bronchial thermoplasty procedure in the past 12 months or planned during the study period.

    General medical history

  9. Weight <40 kg.
  10. Current smoking within the past year or a smoking history of >10 packyears. Smoking includes tobacco, vaping, and/or marijuana use.
  11. Known or suspected alcohol or drug abuse.
  12. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite antihypertensive therapy.
  13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to randomization.
  14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C.
  15. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent, and assent when applicable, that has not been treated with or has failed to respond to standard of care therapy.
  16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements.
  17. Known or suspected noncompliance with medication.
  18. Unwillingness or inability to follow the procedures outlined in the protocol.

    Clinical safety labs

  19. Absolute neutrophil count <2.000x10⁹/L at Screening.
  20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 at Screening (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [Levey et al, 2009] for age ≥18 years at screening; using the Bedside Schwartz [Schwartz and Work, 2009] eGFR formula for age <18).
  21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at screening confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.

    Cardiac safety

  22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction <25%.
  23. History of major adverse cardiovascular event (MACE) within 3 months prior to randomization.
  24. History of cardiac arrhythmia within 3 months prior baseline that is not controlled by medication or via ablation.
  25. History of long QT syndrome.
  26. Corrected QT interval by Fridericia (QTcF) interval >450 ms for males and >470 ms for females at Screening or QTcF ≥480 ms for participants with bundle branch block.
  27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening, including resting heart rate <45 beats per minute (bpm) or >100 bpm.


  28. Pregnant women or women breastfeeding.
  29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).

For this study, rescreening may only be permitted under specific circumstances and only after contact with a Sponsor Clinical representative.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05748600

Layout table for location contacts
Contact: EXHALE Recruiting 888-584-9281 clinicaltrials@areteiatx.com

Layout table for location information
United States, California
Research Site 20001-003 Recruiting
West Covina, California, United States, 91790
United States, Florida
Research Site 20001-048 Recruiting
Aventura, Florida, United States, 33180
Research Site 20001-051 Not yet recruiting
Brandon, Florida, United States, 33511
Research Site 20001-067 Not yet recruiting
Hialeah, Florida, United States, 33016
Research Site US-40001-015 Recruiting
Kissimmee, Florida, United States, 34744
Research Site 20001-004 Recruiting
Tampa, Florida, United States, 33607
United States, Missouri
Research Site 20001-074 Recruiting
Saint Charles, Missouri, United States, 63301
United States, Oklahoma
Research Site US-40001-038 Recruiting
Edmond, Oklahoma, United States, 73034
Sponsors and Collaborators
Areteia Therapeutics
Layout table for investigator information
Principal Investigator: Mona Bafadhel, MD Guy's and St Thomas' NHS Foundation Trust
Layout table for additonal information
Responsible Party: Areteia Therapeutics
ClinicalTrials.gov Identifier: NCT05748600    
Other Study ID Numbers: AR-DEX-22-03
2022-003005-30 ( EudraCT Number )
First Posted: February 28, 2023    Key Record Dates
Last Update Posted: March 3, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Areteia Therapeutics:
Uncontrolled Asthma
Asthma Attack
forced expiratory volume
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Eosinophilia
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Hypereosinophilic Syndrome
Leukocyte Disorders
Hematologic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents